Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life

International Journal of Hematology

Volumn 76, Issue 4, 2002, Pages 365-369

  Miller, Steve ^a   Sharda, Shalini ^a   Rodrigue, James ^a   Mehta, Paulette ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Bone marrow transplantation; Graft versus host disease; Quality of life; Thalidomide

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EATING DISORDER; FATIGUE; GRAFT VERSUS HOST REACTION; HEALTH CARE; HUMAN; SLEEP PATTERN; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; CASE CONTROL STUDY; CHRONIC DISEASE; NEOPLASM; QUALITY OF LIFE; QUESTIONNAIRE;

CASE-CONTROL STUDIES; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 85047693312     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982698     Document Type: Article

References (20)

1. Mehta P, Kedar A, Graham Pole J, Skoda-Smith S, Wingard JR. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Pediatrics. 1999;103:44-49.
2. Cole CH, Rogers PC, Pritchard S, Phillips G, Chan KW. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant. 1994;14:937-942.
3. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-1058.
4. Baker F, Wingard JR, Curbow B, et al. Quality of life of bone marrow transplant long term survivors. Bone Marrow Transplant. 1994;13:589-596.
5. Yeh SS, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr. 1999;70:183-197.
6. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997;336:1487-1493.
7. Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. J Infect Dis. 1999;180:61-67.
8. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long term medical outcomes and quality of life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol. 2002;20:2334-2343.
9. Heinonen H, Volin L, Uutela A, Zevon M, Barrick C, Ruutu T. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation. Ann Hematol. 2001;80:137-143.
10. Saleh US, Brockopp DY. Quality of life one year following bone marrow transplantation: psychometric evaluation of the quality of life in bone marrow transplant survivors tool. Oncol Nurs Forum. 2001;28:1457-1464.
11. Curbow B, Somerfield MR, Baker F, Wingard JR, Legrow MW. Personal changes, dispositional optimism, and psychological adjustment to bone marrow transplantation. J Behav Med. 1993;16:423-443.
12. Ferrell B, Grant M, Schmidt GM, et al. The meaning of quality of life for bone marrow transplant survivors. Part 2. Improving quality of life for bone marrow transplant survivors. Cancer Nurs. 1992;15:247-253.
13. Fromm K, Andrykowski MA, Hunt J. Positive and negative sequelae of bone marrow transplantation: implications for quality of life assessment. J Behav Med. 1996;19:221-250.
14. Andrykowski MA, Bady MJ, Hunt JW. Positive psychosocial adjustment in potential bone marrow transplant recipients: cancer as a psychosocial transition. Psychooncology. 1993;2261-276.
15. Andrykowski MA, Greimer CB, Altmaier EM, et al. Quality of life following bone marrow transplantation: findings from a muticentre study. Br J Cancer. 1995;71:1322-1329.
16. Andrykowski MA, Henslee PJ, Farrall MG. Physical and pyschosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Tranplant. 1989;4:75-81.
17. Savard J, Morin CM. Insomnia in the context of cancer: a neglected problem. J Clin Oncol. 2001;19:895-908.
18. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother. 2002;56:4-12.
19. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002;53:629-657.
20. Combe B. Thalidomide: new indications? Joint Bone Spine. 2001;68:582-587.